BSEGennex Laboratories LtdMinimalNeutral
Announced Mon, 1 Jun · 15:24 IST

Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication on Audited (Standalone and Consolidated) Financial Results for the Quarter ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.2%1-day move
₹11.83
prior close
₹11.26
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5-5.2-5.3-7.4-8.4-10.3-12.3-7.2-10.7
Up moveDown movePending
AI summary

Gennex Laboratories Ltd has submitted copies of the newspaper publication of its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, as required under Regulation 47 of SEBI (LODR) Regulations, 2015. The results were approved by the Board of Directors at a meeting held on May 30, 2026, and were published in Business Standard (English) and Saksham (Telugu) on June 01, 2026. From the published table, total income from operations for Q4 FY26 (standalone) stood at around ₹2,193.26 lakhs versus ₹1,093.26 lakhs in Q4 FY25, indicating strong year-on-year growth. However, standalone net profit after tax for the full year FY26 was approximately ₹1,037.26 lakhs compared to ₹1,323.61 lakhs in FY25, showing a year-on-year decline in profitability. The full detailed results are available on the BSE website and the company's website.

Likely market impact

This is a routine SEBI compliance filing (newspaper publication of already-approved results) and not a new material event. Shareholders should note the apparent divergence between healthy revenue growth in Q4 and an overall decline in full-year net profit versus the previous year, and review the detailed results on BSE for deeper context before drawing conclusions.